MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 582-588

  Naito, Mikihiko ^a   Matsuba, Yasuhiro ^a,c   Sato, Shigeo ^b   Hirata, Hiroshi ^d   Tsuruo, Takashi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c Drug Discovery Institute   (Japan)

^d Preclinical Development Department   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; QUINOLINE DERIVATIVE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL LINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MITOSIS; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; PACLITAXEL; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036190935     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Multidrug resistance: Molecular mechanisms and clinical relevance
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
3. Expression of a full-length cDNA for the human "MDR" gene confers resistance to colchicine, doxorubicin, and vinblastine
4. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
5. Cyclosporins as drug resistance modifiers
6. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells
7. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues
8. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus
9. Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine
10. Structure-activity relation ship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer
11. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines
12. Reversal of multidrug resistance by a novel quinoline derivative, MS-209
13. Interaction of docetaxel ("Taxotere") with human P-glycoprotein
14. Docetaxel (Taxotere). A review of preclinical and clinical experience. Part 1: Preclinical experience
15. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes
16. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
17. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography
18. A nonlinear least squares program based on differential equations. MULTI (RUNGE), for microcomputers
19. Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells
20. Docetaxel (Taxotere). A review of preclinical and clinical experience. Part II: Clinical experience
21. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer
22. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer
23. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer
24. A late phase II study of RP 56976 (docetaxel) in patients with advanced or recurrent breast cancer
25. Efficacy of docetaxel for recurrent breast cancer: Evaluation based on chemosensitivity test and clinical response
26. Phase II study of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
27. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
28. Antitumor activity of docetaxel
29. Circumvention of multidrug resistance by a quinoline derivative, MS-209 in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil
30. Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells
31. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene
32. The multidrug resistance protein family